We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $2.19B
1-Year Est. Return 374.99%
This Fund
S&P 500
This Quarter Est. Return
+8.25%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.7B
AUM Growth
+$337M
Cap. Flow
+$308M
Cap. Flow %
18.12%
Top 10 Hldgs %
39.64%
Holding
351
New
78
Increased
102
Reduced
60
Closed
41

Top Buys

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$40.1M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$37.1M
3
DNLI icon
Denali Therapeutics
DNLI
+$36.2M
4
INSP icon
Inspire Medical Systems
INSP
+$27.3M
5
VIR icon
Vir Biotechnology
VIR
+$21.9M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$39.4M
2
RAPT
RAPT Therapeutics
RAPT
+$17.3M
3
CDTX
Cidara Therapeutics
CDTX
+$13.2M
4
FULC icon
Fulcrum Therapeutics
FULC
+$10.4M
5
ABUS icon
Arbutus Biopharma
ABUS
+$9.98M

Sector Composition

Rank Sector Weight
1 Healthcare 88.42%
2 Miscellaneous 9.68%
3 Financials 1.51%
4 Technology 0.08%
5 Industrials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JSPR icon
276
Jasper Therapeutics
JSPR
$23.3M
$123K 0.01%
140,000
– –
NEUP
277
Neuphoria Therapeutics
NEUP
$20.3M
$122K 0.01%
30,000
– –
MIST icon
278
Milestone Pharmaceuticals
MIST
$144M
$119K 0.01%
100,000
-100
-0.1% -$175
ARCT icon
279
Arcturus Therapeutics
ARCT
$432M
$116K 0.01%
+15,000
New +$109K
MGNX icon
280
MacroGenics
MGNX
$263M
$116K 0.01%
+40,000
New +$85.3K
CCCC icon
281
C4 Therapeutics
CCCC
$474M
$113K 0.01%
+43,000
New +$101K
RXRX icon
282
Recursion Pharmaceuticals
RXRX
$1.79B
$107K 0.01%
35,000
– –
DSGN icon
283
Design Therapeutics
DSGN
$946M
$106K 0.01%
+10,000
New +$101K
GOSS icon
284
Gossamer Bio
GOSS
$83.2M
$94.5K 0.01%
287,531
+75,000
+35% +$118K
IMMX icon
285
Immix Biopharma
IMMX
$992M
$91.1K 0.01%
10,000
-40,000
-80% -$294K
STI icon
286
CALL
Solidion Technology
STI
$64.3M
$85.2K 0.01%
13,500
– –
LITS
287
Lite Strategy Inc
LITS
$33.4M
$78.1K ﹤0.01%
67,292
– –
VERU icon
288
Veru
VERU
$44.8M
$77.3K ﹤0.01%
35,000
– –
KYNB
289
Kyntra Bio
KYNB
$32.5M
$71K ﹤0.01%
10,469
– –
CLOV icon
290
Clover Health Investments
CLOV
$2.25B
$70.4K ﹤0.01%
40,000
-8,300
-17% -$18K
BMEA icon
291
Biomea Fusion
BMEA
$125M
$66.4K ﹤0.01%
43,420
– –
NMRA icon
292
Neumora Therapeutics
NMRA
$261M
$64.5K ﹤0.01%
33,100
-17,500
-35% -$45.3K
OGN icon
293
Organon & Co
OGN
$3.61B
$59.9K ﹤0.01%
10,000
-25,000
-71% -$188K
ESPR
294
DELISTED
Esperion Therapeutics
ESPR
$58.6K ﹤0.01%
+21,400
New +$67.7K
MREO
295
Mereo BioPharma
MREO
$40.3M
$49.5K ﹤0.01%
150,000
– –
ANTX icon
296
AN2 Therapeutics
ANTX
$211M
$47.4K ﹤0.01%
+13,861
New +$28.6K
ASPCR
297
A SPAC III Acquisition Corp Right
ASPCR
$42.4K ﹤0.01%
215,000
– –
AQST icon
298
Aquestive Therapeutics
AQST
$630M
$41.5K ﹤0.01%
+10,000
New +$40.6K
ATYR
299
aTyr Pharma
ATYR
$53M
$39.5K ﹤0.01%
50,685
– –
BCAB icon
300
BioAtla
BCAB
$2.9M
$36.7K ﹤0.01%
4,562
+900
+25% +$10.5K
10 11
12
13 14

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $2.19B AUM 50.16% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $2.18B AUM 23.73% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $2.18B AUM 30.3% 1-Year Est. Return
BOI
Bank of Italy Rome, Italy $2.2B AUM 1.53% 1-Year Est. Return

ADAR1 Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, ADAR1 Capital Management held 351 positions worth $1.7B, up 25% from $1.36B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

ADAR1 Capital Management deployed $308M of net new capital in Q1 2026, opening 78 new positions and adding to 102 existing holdings. Its largest new stake was Beam Therapeutics: 1,446,375 shares worth $34.5M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 89% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Fulcrum Therapeutics, an estimated $10.4M trimmed.

  • ADAR1 Capital Management's largest Q1 2026 buy was Beam Therapeutics: 1,446,375 shares worth $34.5M.
  • ADAR1 Capital Management added most to Crinetics Pharmaceuticals in Q1 2026, an estimated $37.1M increase.
  • ADAR1 Capital Management's biggest Q1 2026 reduction was Fulcrum Therapeutics, cutting an estimated $10.4M.
  • ADAR1 Capital Management fully exited Avidity Biosciences in Q1 2026, selling an estimated $39.4M.
  • ADAR1 Capital Management's ten largest holdings make up 40% of its $1.7B portfolio in Q1 2026.
  • ADAR1 Capital Management opened 78 new positions and closed 41 in Q1 2026.
  • ADAR1 Capital Management's portfolio value rose 25% quarter-over-quarter to $1.7B.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.